- AU$572.78m
- AU$485.28m
- AU$395.47m
- 68
- 59
- 63
- 67
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.28 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.37 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.75% | ||
| Return on Equity | -23.75% | ||
| Operating Margin | -31% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 457.77 | 401.47 | 157.61 | 190.31 | 395.46 | 426.55 | 457.6 | -5.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.
Directors
- Frank Condella NEC (67)
- Scott Richards CEO (58)
- Ian Scholes NVC (66)
- Peter Paltoglou CFO
- Laura Loftus SEC
- Carolyn Myers DRC (62)
- Patrick Blake NID (58)
- Nancy Dolan NID (70)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 18th, 2005
- Public Since
- June 29th, 2007
- No. of Shareholders
- 10,542
- No. of Employees
- 900
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 81,245,827
- Address
- 1538 Main North Road, Salisbury South, ADELAIDE, 5106
- Web
- https://www.maynepharma.com/
- Phone
- +61 882092666
- Auditors
- BDO Audit Pty Ltd
Upcoming Events for MYX
Similar to MYX
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
What is the Mayne Pharma share price?
As of Today at 21:56 UTC, shares in Mayne Pharma are trading at AU$7.05. This share price information is delayed by 15 minutes.
How has the Mayne Pharma share price performed this year?
Shares in Mayne Pharma last closed at AU$7.05 and the price had moved by +5.86% over the past 365 days. In terms of relative price strength the Mayne Pharma share price has outperformed the ASX All Ordinaries Index by +4.27% over the past year.
What are the analyst and broker recommendations for Mayne Pharma?
The overall consensus recommendation for Mayne Pharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Mayne Pharma dividend yield?
Mayne Pharma does not currently pay a dividend.
Does Mayne Pharma pay a dividend?
Mayne Pharma does not currently pay a dividend.
When does Mayne Pharma next pay dividends?
Mayne Pharma does not currently pay a dividend.
How do I buy Mayne Pharma shares?
To buy shares in Mayne Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mayne Pharma?
As of the previous close price of AU$7.05, shares in Mayne Pharma had a market capitalisation of AU$572.78m.
Where are Mayne Pharma shares listed?
Here are the trading details for Mayne Pharma:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: MYX
What kind of share is Mayne Pharma?
Based on an overall assessment of its quality, value and momentum Mayne Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mayne Pharma share price forecast for 2025?
The analyst consensus target price for shares in Mayne Pharma is AU$7.40. That is 4.96% above the last closing price of AU$7.05.
Analysts covering Mayne Pharma currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.08 for the next financial year.
Find out moreWhat is the trend in the Mayne Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mayne Pharma. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +53.59%.
As of the last closing price of AU$7.05, shares in Mayne Pharma were trading +36.88% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mayne Pharma PE Ratio?
The Mayne Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$7.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mayne Pharma?
Mayne Pharma's management team is headed by:
- Frank Condella - NEC
- Scott Richards - CEO
- Ian Scholes - NVC
- Peter Paltoglou - CFO
- Laura Loftus - SEC
- Carolyn Myers - DRC
- Patrick Blake - NID
- Nancy Dolan - NID